The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Real-time continuous glucose monitoring (rt-CGM) reduced large-for-gestational-age (LGA) births in women with gestational diabetes.

Topline data were announced from a phase 3 trial evaluating ersodetug in patients aged 3 months to 45 years with congenital hyperinsulinism.

Higher body dissatisfaction was linked to more severe eating disorder, depressive symptoms in monozygotic and dizygotic twin difference analyses. HealthDay News — Body dissatisfaction may causally ...

The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

Young-onset hypertension increases the risk of cardiovascular and kidney outcomes compared with late-onset hypertension in type 2 diabetes.

A data monitoring committee recommended stopping the phase 3 trials of efgartigimod in thyroid eye disease due to lack of efficacy.

Giredestrant shows significant improvement in iDFS in patients with early-stage, HR-positive, HER2-negative breast cancer.

Atezolizumab plus standard therapy was not associated with improved survival in advanced recurrent ovarian cancer.

The FDA has expanded the approval of Addyi to include the treatment of hypoactive sexual desire disorder in women less than 65 years.

Second-generation automated insulin delivery (AID) systems improve glycemic control and treatment satisfaction in type 1 diabetes.